Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]

Insulet (Nasdaq:PODD) shares were unmoved after hours today on second-quarter results that topped the consensus revenue forecast.

The Acton, Massachusetts-based automated insulin delivery technology developer posted losses of, or 50¢ per share, on sales of $299.4 million for the three months ended June 30, 2022, for a $10 million bottom-line slide deeper into the red on sales growth of 13.8%.

Get the full story at our sister site, Drug Delivery Business News.